The effects of ethyl pyruvate against experimentally induced cisplatin ototoxicity in rats

Basit Öğe Kaydı
dc.contributor.authorAyral, Muhammed
dc.contributor.authorToprak, Serdar Ferit
dc.date.accessioned2024-04-24T16:24:41Z
dc.date.available2024-04-24T16:24:41Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: Cisplatin (CDDP) is a widely used antineoplastic drug. However, its use is limited due to the ototoxic side effects. In this study, the effects of ethyl pyruvate (EP), known for its antioxidant and anti-inflammatory effects, against CDDP ototoxicity were investigated. Methods: Thirty-two Wistar albino rats (n:8) were used in this study. CDDP was administered i.p. as a single dose of 15 mg/kg/day in order to cause ototoxicity. EP was applied i.p. at a dose of 50 mg/kg/day for 7 days. Results: When the Auditory Brainstem Responses (ABR) and Distortion Product Otoacoustic Emissions (DPOAE) tests carried out in the pre-treatment and post-treatment periods were examined, it was observed that the hearing functions were significantly impaired with the CDDP application, while a significant improvement was observed in the CDDP + EP group. Compared to the control group, the CDDP group had significantly higher malondialdehyde (MDA) levels and significantly lower glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT) levels. In the CDDP + EP group, there was no deterioration in MDA, SOD and CAT levels that was observed in the CDDP group. The increase in pro-inflammatory cytokine (IL-1 beta, IL-6 and TNF-alpha) levels caused by CDDP administration was observed to be significantly decreased in the CDDP + EP group. Conclusions: Hearing tests and biochemical results show that ethyl pyruvate is protective against cisplatin ototoxicity with its antioxidant and anti-inflammatory effects.en_US
dc.identifier.doi10.1080/08990220.2021.1984875
dc.identifier.endpage352en_US
dc.identifier.issn0899-0220
dc.identifier.issn1369-1651
dc.identifier.issue4en_US
dc.identifier.pmid34635013
dc.identifier.startpage347en_US
dc.identifier.urihttps://doi.org/10.1080/08990220.2021.1984875
dc.identifier.urihttps://hdl.handle.net/11468/16815
dc.identifier.volume38en_US
dc.identifier.wosWOS:000706654900001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofSomatosensory and Motor Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCisplatinen_US
dc.subjectOtotoxicityen_US
dc.subjectEthyle Pyruvateen_US
dc.subjectPro-Inflammatory Cytokineen_US
dc.subjectTnf-Alphaen_US
dc.subjectAuditory Brainstem Responsesen_US
dc.subjectDistortion Product Otoacoustic Emissionsen_US
dc.subjectReactive Oxygen Speciesen_US
dc.titleThe effects of ethyl pyruvate against experimentally induced cisplatin ototoxicity in ratsen_US
dc.titleThe effects of ethyl pyruvate against experimentally induced cisplatin ototoxicity in rats
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu